Alpha Tau Medical Ltd (DRTS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alpha Tau Medical Ltd (DRTS) has a cash flow conversion efficiency ratio of 0.000x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.78K) by net assets ($89.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Alpha Tau Medical Ltd (DRTS) liquidity interval to measure how many days the company can operate on defensive assets alone.
Alpha Tau Medical Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Alpha Tau Medical Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alpha Tau Medical Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alpha Tau Medical Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Technocraft Industries (India) Limited
NSE:TIIL
|
0.070x |
|
Jenkem Technology Co Ltd
SHG:688356
|
-0.013x |
|
Brisa Bridgestone Sabanci Lastik Sanayi ve Ticaret AS
IS:BRISA
|
0.058x |
|
Guangdong Piano Customized Furniture Co Ltd
SHE:002853
|
0.016x |
|
Surya Roshni Limited
NSE:SURYAROSNI
|
0.098x |
|
Nanjing Medlander Medical Technology Co. Ltd. A
SHG:688273
|
N/A |
|
Fuan Pharmaceutical Group Co
SHE:300194
|
0.023x |
|
SurModics Inc
NASDAQ:SRDX
|
0.013x |
Annual Cash Flow Conversion Efficiency for Alpha Tau Medical Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Alpha Tau Medical Ltd from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see DRTS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $62.67 Million | $-19.78 Million | -0.316x | -48.50% |
| 2023-12-31 | $84.47 Million | $-17.96 Million | -0.213x | +5.94% |
| 2022-12-31 | $105.66 Million | $-23.88 Million | -0.226x | -166.54% |
| 2021-12-31 | $-34.78 Million | $-11.81 Million | 0.340x | -60.52% |
| 2020-12-31 | $-8.43 Million | $-7.25 Million | 0.860x | -97.60% |
| 2019-12-31 | $-193.00K | $-6.91 Million | 35.803x | -- |
About Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending cl… Read more